Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
Clin Cardiol. 2012 Oct;35(10):610-8. doi: 10.1002/clc.22020. Epub 2012 Jun 15.
We examined the impact of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) on clinical outcomes in patients with bifurcation lesions treated with drug-eluting stents.
We hypothesized that NSTE-ACS would be attributable to the increased risk of major adverse cardiac events (MACE) in bifurcation percutaneous coronary intervention.
We enrolled 1668 patients, using data from a multicenter real-world bifurcation registry. The primary objective was to compare the 2-year cumulative risk of MACE in patients with NSTE-ACS to those with stable angina. Major adverse cardiac events were defined as the composite endpoint of cardiac death, myocardial infarction (MI), and target-lesion revascularization.
Non-ST-segment elevation acute coronary syndrome was seen in 969 (58.1%) patients and stable angina in 699. Major adverse cardiac events occurred in 7.3% of NSTE-ACS patients and in 5.2% with stable angina (P = 0.042). However, cardiac death, MI, and target-lesion revascularization were similar between the 2 groups. We stratified patients with NSTE-ACS into those with non-ST-segment elevation MI and those with unstable angina. Cumulative risks of 2-year MACEs were 7.0% in non-ST-segment elevation MI patients and 7.5% in unstable angina patients (P = 0.87). In the NSTE-ACS cohort, the baseline lesion length in the side branch (adjusted hazard ratio [HR]: 1.04, 95% confidence interval [CI]: 1.01-1.07, P = 0.022), paclitaxel-eluting stents in the main vessel (adjusted HR: 2.02, 95% CI: 1.21-3.40, P = 0.008), and final kissing ballooning (adjusted HR: 1.88, 95% CI: 1.10-3.21, P = 0.021) were independent predictors of MACE.
Compared with stable angina patients, the NSTE-ACS patients who underwent bifurcation percutaneous coronary intervention had an increased risk of MACE during the 2-year follow-up.
我们研究了非 ST 段抬高型急性冠状动脉综合征(NSTE-ACS)对接受药物洗脱支架治疗的分叉病变患者临床结局的影响。
我们假设 NSTE-ACS 会导致分叉经皮冠状动脉介入治疗中主要不良心脏事件(MACE)风险增加。
我们纳入了来自多中心真实世界分叉登记处的 1668 例患者的数据。主要目的是比较 NSTE-ACS 患者与稳定性心绞痛患者的 2 年 MACE 累积风险。主要不良心脏事件定义为心脏死亡、心肌梗死(MI)和靶病变血运重建的复合终点。
NSTE-ACS 患者 969 例(58.1%),稳定性心绞痛患者 699 例。NSTE-ACS 患者的主要不良心脏事件发生率为 7.3%,稳定性心绞痛患者为 5.2%(P=0.042)。然而,两组间心脏死亡、MI 和靶病变血运重建发生率相似。我们将 NSTE-ACS 患者分为非 ST 段抬高型 MI 患者和不稳定型心绞痛患者。非 ST 段抬高型 MI 患者和不稳定型心绞痛患者 2 年 MACE 的累积风险分别为 7.0%和 7.5%(P=0.87)。在 NSTE-ACS 队列中,侧支病变长度(校正危险比[HR]:1.04,95%置信区间[CI]:1.01-1.07,P=0.022)、主血管内紫杉醇洗脱支架(校正 HR:2.02,95% CI:1.21-3.40,P=0.008)和最终的对吻球囊扩张(校正 HR:1.88,95% CI:1.10-3.21,P=0.021)是 MACE 的独立预测因素。
与稳定性心绞痛患者相比,接受分叉经皮冠状动脉介入治疗的 NSTE-ACS 患者在 2 年随访期间发生 MACE 的风险增加。